Project
Amgen CC-10004-PsA-014 MOSAIK
Completed ยท 2019 until 2021
Rubbert-Roth Andrea, Bartz-Batliner Mira, Neumann Thomas, Sasselli Clelia, Peischl Riana
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2019
End Date
2021
Financing
Industry
Study Design
This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable MTX, on MRI outcomes in subjects with active PsA with
up to 5 years of disease duration (since diagnosis).
Keywords
PsA, Apremilast, MRI
Brief description/objective
A PHASE 4, MULTICENTER, SINGLE-ARM, OPENLABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) ON MRI OUTCOMES IN SUBJECTS WITH PSORIATIC ARTHRITIS